Possible offerHealthcare17 November 2026

Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Aimei Health Technology Co., Ltd
Target
Hera Health Solutions Inc.
Deal value
Not disclosed
Announced
17 November 2026
Status
Possible offer
Sector
Healthcare
Country
United States
Consideration
shares
What we know

Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business combination with Hera Health Solutions Inc. Under the letter of intent, Aimei would acquire 100% of Hera's outstanding equity and equity equivalents in exchange for shares of the combined public company. The terms were disclosed in a Form 8-K under Item 7.01 (Regulation FD Disclosure), signed by chief executive officer Junheng Xie on November 17, 2026. The filing gives no aggregate value or exchange ratio.

Hera is described in the filing as a pharmaceutical technology company headquartered in Memphis, Tennessee. It is developing drug delivery products built on a proprietary biodegradable nanofiber scaffold technology, an electrospinning manufacturing platform and AI-driven formulation capabilities. Its technology is meant to reformulate existing medicines into long-acting implants, patches and other formats with sustained release. Its Hercules AI technology targets formulation development across women's health, infectious diseases, pain management and metabolic disorders.

The letter of intent is non-binding except for certain provisions, including confidentiality and exclusivity. Aimei says it expects to announce further details when a definitive business combination agreement is executed, and it states there is no assurance that one will be signed or that the transaction will close.

The filing lists the remaining steps: negotiating and signing definitive agreements, completing due diligence, and obtaining the required regulatory and shareholder approvals. If a definitive agreement is signed, Aimei or a holding company formed for the transaction intends to file a Form F-4 or Form S-4 registration statement with the SEC containing a preliminary proxy statement/prospectus. A definitive proxy statement/prospectus would then be mailed to Aimei shareholders for a vote on the transaction.

Deal timeline

1 update
  1. Possible offer

    Aimei Health Technology Co., Ltd signs non-binding letter of intent to acquire Hera Health Solutions Inc.

    Item 7.01. Regulation FD Disclosure. On November 14, 2026, Aimei Health Technology Co., Ltd (the “ Company ”) entered into a non-binding letter of intent (the “ LOI ”) for a business combination (the “ Proposed Transaction ”) with Hera Health Solutions Inc., a Tennessee biotechnology and medical device company (“ Hera ”). Under the terms of the LOI, the Company and Hera would become a combined ent

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Aimei Health Technology Co., Ltd

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive